Last reviewed · How we verify
HTIG
HTIG is a humanized anti-TIGIT monoclonal antibody that blocks the TIGIT immune checkpoint to enhance T-cell mediated anti-tumor immunity.
HTIG is a humanized anti-TIGIT monoclonal antibody that blocks the TIGIT immune checkpoint to enhance T-cell mediated anti-tumor immunity. Used for Advanced or metastatic solid tumors (in clinical development).
At a glance
| Generic name | HTIG |
|---|---|
| Sponsor | Zhuhai Trinomab Pharmaceutical Co., Ltd. |
| Drug class | TIGIT inhibitor (monoclonal antibody) |
| Target | TIGIT |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
TIGIT (T-cell immunoreceptor with Ig and ITIM domains) is an inhibitory checkpoint receptor expressed on T cells and NK cells. By blocking TIGIT, HTIG prevents its interaction with ligands (CD155 and CD112) on tumor and antigen-presenting cells, thereby relieving immune suppression and promoting T-cell activation and proliferation against cancer cells. This mechanism complements other checkpoint inhibitors like anti-PD-1/PD-L1 therapies.
Approved indications
- Advanced or metastatic solid tumors (in clinical development)
Common side effects
- Immune-related adverse events (irAEs)
- Fatigue
- Diarrhea
- Rash
Key clinical trials
- Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Anti-Tetanus Toxin Monoclonal Antibody Injection (PHASE1)
- A Phase 4 Study to Evaluate the Effectiveness and Safety of Siltartoxatug Injection for Tetanus Prophylaxis Following Injury
- Study to Compare the Anti-tetanus Neutralizing Antibody Titers and Safety of TNM002 Injection With Human Tetanus Immunoglobulin or Placebo in Adult Volunteers (PHASE2)
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SNA02-48 Injection in Chinese Adult Participants (PHASE1, PHASE2)
- A Phase III Clinical Trail to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity Characteristics of GR2001 Injection (PHASE3)
- Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of the Fully Human Anti-tetanus Toxin Monoclonal Antibody A82 / B86 Injection Combination Formulation (EARLY_PHASE1)
- Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GR2001 in Chinese Healthy Adults (PHASE1, PHASE2)
- Study to Compare the Efficacy and Safety of Passive Immunization With TNM002 Injection and Human Tetanus Immunoglobulin as Prophylaxis Against Tetanus (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |